Why is Alnylam Pharmaceuticals stock climbing today?
Alnylam Pharmaceuticals shares rose 1.7% in pre-open to $209.1 after Raymond James upgraded the stock from Outperform to Strong Buy and set a $420 price target. The upgrade followed a post–Q2 selloff tied to reduced ATTR franchise guidance. Other banks issued constructive notes. The S&P 500 and Dow were up.
How this was made
The 30-second read
Why it matters
A same-day Raymond James upgrade to Strong Buy with a $420 target is presented as the key driver for renewed buying, alongside additional constructive analyst notes and a stronger broader market.
Market read
Traders can treat the upgrade and target as a near-term sentiment catalyst, especially given the stock’s proximity to recent lows.
What to watch
Other analyst actions cited are mixed (e.g., Barclays trimmed its price target), suggesting upside may be capped without follow-on fundamental catalysts.
Background
The stock had fallen about 35% since early July after Q2 earnings included a guidance reduction for the ATTR franchise, leaving shares near the 52-week low.
Ticker impact
Alnylam shares rose pre-open after Raymond James upgraded it to Strong Buy and set a $420 price target following a post-Q2 selloff.
Near-term upside bias versus the prior selloff, with follow-through dependent on whether additional analyst notes and broader risk-on persist.
The article attributes today’s move to a same-day upgrade and cites the prior guidance-related decline, but it does not add new company fundamentals beyond the analyst action.
Market effects
Positive read-through for biotech sentiment if analyst upgrades continue after earnings-related guidance resets.
Primarily US-focused via S&P 500 and Nasdaq strength supporting growth/biotech risk appetite.
Limited direct global linkage; macro tailwind is broad rather than company-specific.
Counterpoint
The rally may fade if the underlying issue from the Q2 guidance reduction for the ATTR franchise is not resolved by new data or updated company guidance.
Key entities
- companyAlnylam Pharmaceuticals
Subject of the article; shares are described as rising pre-open on an analyst upgrade after a post-earnings selloff.
- analyst_firmRaymond James
Upgraded ALNY from Outperform to Strong Buy and set a $420 price target in the article.
- analyst_firmScotiabank
Issued a positive forecast on the stock today per the article.
- analyst_firmUBS
Weighed in constructively on August 2 per the article.
- analyst_firmBarclays
Maintained Overweight but trimmed its price target to $450 from $527 per the article.
